

BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

ENVIRONMENTAL SOCIAL AND GOVERNANCE REPORT



CONTENTS

	About this Report	1
	Board of Directors' Message	2
	2024 Performance Highlights	3
	Key Events of 2024	5
	About BioSino	7
	Recognition and Awards	8
	Board Diversity	9
01	Governance Structure	9
Governance	Internal Control and Risk Management	10
	Business Ethics and Anti-corruption Policy	11
	Business Information Security	11
	Business Information Disclosure and Security	12
	Stakeholder Identification and Engagement	12
	Materiality Issue Determination	14
00	 Healthcare Inclusivity 	16
02	 Technology and Innovation 	17
Product Research and Development and Innovation	 Product and Service Quality 	20

03 Green and Low-carbon- Development	
04 Talent Development	
05 Ecological Co-construction	
	Inde: Read



	Environmental Protection Policies and Objectives	24
	Addressing Climate Change	24
	Low-carbon Office	28
	Emission Management, the Utilization of Resou	rce
	and Energy	29
		21
	Corporate culture and the concept of employing	31
	Talent Training and Retention	31
	Occupational Health and Safety	36
	Strategic Cooperation	37
	Empowering Teams and Industry Growth	38
	Supply Chain ESG Management	38
	Participate in the Formulation of Industry Standa	ırds
	and Groups Standards	41
	Exhibition Appearances	42
	Community Involvement	43
х ′	Table of HKEX ESG Reporting Code	44
de	r Feedback	47

ABOUT THIS REPORT

Overview

This report is the fourth environmental, social and governance report independently issued by Biosino Bio-Technology and Science Incorporation, hereinafter referred to as "Biosino", the "Company" and "we", which comprehensively reflects the Company's performance in ESG. This report covers the performance of the financial year from January 1, 2024 to December 31, 2024. Some related information is traced out of the Reporting Period.

Report methodology

This report is prepared in accordance with the requirements of Appendix C2 "Environmental, Social and Governance Reporting Code" of the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited. In addressing climate change disclosure, reference is made to The Stock Exchange of Hong Kong Limited's "Guidance on the Recommended Disclosure of Climate-related Information according to the TCFD Recommendations."

Report scope

The policies and data provided in this report covers the company and its subsidiaries, and the scope of the report is consistent with the annual report. The data and cases in this report are mainly from the company's statistic reports and relevant documents. The disclosure boundary is: (a) Subsidiaries with consolidated financial statements; (b) Subsidiaries actually controlled; (c) The company has been put into operation for two natural years or more.

The board of directors of promises that there are no false records and misleading statements in this report, and is responsible for the authenticity, accuracy and completeness of its contents.

Report language

The report is drafted in Chinese and English.

Confirmation and approval

This report was approved by the Board on March 31, 2025, following confirmation by the board of directors.

Acquisition method

This report is provided in both paper and electronic forms. The electronic version of this report can be viewed and downloaded from the official website of BIOSINO, and published on the website of the stock exchange at the same time.

BOARD OF DIRECTOR' MESSAGE

Dear colleagues, business partners, and friends from all sectors of society,

In this crucial moment of looking back on the past and envisioning the future, it is my honor to share with you, through the 2024 ESG Report, Biosino's explorations and practices in advancing sustainable development over the past year.

In the past year, the global in vitro diagnostic (IVD) industry has faced complex and changing challenges, from the intensification of market competition, the acceleration of technological iteration, to the higher expectations of society for medical and health responsibilities. However, Biosino has always remained true to its original aspiration, integrated the ESG concept into every aspect of the company's operations, actively responded to challenges, and strived to create comprehensive economic, social, and environmental values.

In terms of driving development through scientific and technological innovation, 2024 was a year full of fruitful achievements. We continued to increase our investment in research and development and launched a series of innovative products, such as the "King Kong 9000" intelligent laboratory automation system. This not only demonstrates our technical strength but also serves as a powerful proof of our commitment to providing intelligent and efficient services to our customers. Through continuous innovation, we hope to provide more advanced diagnostic technologies and solutions for the global medical and health cause, helping to improve the health level of humanity.

In fulfilling our social responsibilities, we have actively participated in public welfare activities and made efforts to provide medical support to vulnerable groups in society. We are well aware that medical and health care is related to the well-being of everyone. As a member of the IVD industry, we have the responsibility to contribute to narrowing the gap in medical resources. At the same time, we attach great importance to the growth and development of our employees, and are committed to creating a diverse and inclusive working environment, providing our employees with broad career development opportunities and rich training opportunities, so that every employee from Biosino can realize their own value within the company.

Environmental responsibility is also a key point that we are focusing on. Biosino has always adhered to the corporate mission of "Beautifying Life with Technology". With a high sense of responsibility, we actively practice the ESG concept. While pursuing economic development, we are committed to creating greater value for society and promoting the sustainable progress of the industry. In the process of production and operation, we always uphold the concept of green development. Through measures such as optimizing production processes and improving resource utilization efficiency, we reduce the impact on the environment and strive to achieve a balance between economic benefits and environmental benefits.

Looking ahead, we will continue to deepen our ESG strategy and continuously enhance the company's sustainable development capabilities. In terms of technological innovation, we will continue to invest, keep up with the development trends of the industry, and provide our customers with higher-quality and more intelligent products and services. In terms of social responsibilities, we will further strengthen cooperation with all sectors of society, actively participate in more public welfare projects, and make greater contributions to the social health cause. In terms of environmental protection, we will continuously explore and apply more environmentally friendly production technologies and processes, and contribute to the protection of our planet.

I would like to express my gratitude to every employee for their hard work, to our business partners for their trust and support, and to all sectors of society for their attention to and supervision of Biosino. Let us move forward hand in hand, forge ahead on the path of sustainable development, beautify life with technology, and contribute to the development of the global medical and health cause!

2024 PERFORMANCE HIGHLIGHTS

01 Financial Performance	02 Corporate Governance	03 Product Innovation	04 Green and Low Carbon
Annual revenue for 2024: 263.06933 million yuan	10 Board members 3 Supervisory board members 16 ESG committee members 24 Significant ESG issues. 100% Board member participation in business ethics training courses	33.4176 million yuan R&D investment for 2024 104 Number of R&D center staff 85 Granted invention patents 60 Granted utility model patents 11 Granted design patents	Total carbon emissions (Scope 1+Scope 2) for 2024 12999.577 tCO2e Carbon emission intensity 0.0493 tCO2e per ten thousand RMB
	5 Board meetings 2 Shareholder meetings 2 Supervisory board meetings	26 35 Software copyrights Trademarks 48 Published papers 345 Product registration certificates held	



Ecological Co-construction



Supplier ESG training session

2



06

Employee Development

International and domestic exhibitions

499

47.7%

100%

100%

100%

100%

Occupational injury insurance coverage rate for employees

100%

Employee health check coverage rate

100%

KEY EVENTS OF 2024

- Passed the "High-Tech Enterprise" certification again.
- Biosino Suzhou achieved the honor of Jiangsu Private Technology Enterprise.
- Selected as the Leading Enterprises in Enterprise Innovation Credit in Beijing for 2024

- Obtain the CNAS Laboratory Accreditation Certificate.
- Gain the TUV Medical Device Quality Management System Certification Certificate.

Product Innovation

- Obtain certification and launch the fully automated sample processing system on the market
- Make the new KingKong9000 smart laboratory pipeline debut brilliantly in Chongging
- Jointly establish an industry-university-research joint laboratory by the East China Industrial Research Institute of Life Sciences of Peking University and Biosino Precision Medicine Laboratory
- Officially release the fully automated flow workstation at the Hangzhou exhibition
- Shortlist Biosino's SinoCyte X scientific research flow cytometer for the "3i Award Outstanding New Products of Scientific Instruments"

- Increase the upper limit of the linear range of the β 2-microglobulin assay kit (latex immunoturbidimetric method)
- Adopt the cystathionine method for the homocysteine assay kit (enzyme cycling method) to keep the reagent cost relatively low
- Obtain certification and launch the self-produced flow reagent for platelet projects on the market
- Get the 4-laser 21-color SinoCyte X high-end (scientific research) flow cytometer approved for

listing

Green and Low Carbon

Since the smart power distribution room was put into operation, it has been operating safely and stably, saving 200,000 yuan in electricity bills and reducing approximately 140 tons of CO2e.



Since the automatic steam operation and maintenance system was put into use, it has been operating safely and stably.



Ecological Co-construction

- Showcased newly launched products and technologies at the Arab International Medical Laboratory Instruments and Equipment Exhibition.
- Showcased star products at the CACLP (Chongqing) Exhibition.
- Showcased newly launched products at the 13th OCLM (Oriental Conference on Laboratory Medicine)
- Showcased newly launched products at NCLM in Hangzhou
- Showcased the bedside cardiac biomarker detector PATHFAST at the China Heart Congress (CHC) in Beijing.
- Participate in the 18th Academic Conference on Laboratory Medicine of Beijing Medical Association
- Participate in the 2024 International Medical and Medical Devices Fair in Düsseldorf, Germany
- Participate in the implementation of the industry standard of "Glucose Assay Kit (Enzymatic Method)" by drafting and signing
- Participated in the drafting and implementation of the industry standard for "Glycerol Triace-tate Determination Kit(Enzymatic Method)."
- The President of Biosino and relevant senior executives visited the Hong Kong Institute of Innovation of the Chinese Academy of Sciences for exchange.
- A holding company under Biosino and a unit under Country Garden Services sign a national strategic cooperation agreement
- Biosino give a report on "Performance Verification and Development Trends of Domestic Flow Cytometry" in Hefei.

Giving back to Society

- Participate in the "Spring Revives Changping, Beautifies Our Homeland" themed environmental improvement activity in Changping District where the company is located.
- Led the inter-provincial alliance procurement for renal function and myocardium in Jiangxi Province, with Biosino advancing steadily into Group A.





ABOUT BIOSINO

Biosino Bio-Technology and Science Incorporation is a high-tech listed company founded and controlled by the Institute of Biophysics, Chinese Academy of Sciences. The company primarily engages in the research, development, production, sales, and service of in vitro diagnostic (IVD) products. Since its establishment in 1973, it has always been guided by the need to meet public welfare demands, actively promoting the development of the national IVD industry, creating an independent innovation system integrating production, study, research, and application. It explores an "international, group-based, and compound" business model, constructing a "systematic, serialized, integrated, and intelligent" all-inone industry chain to enhance core competitiveness and establish a leading position in the industry.

Since pioneering China's enzymatic mono and dual biochemical reagents, Biosino has, over the years, developed a complete biochemical testing product platform and diversified IVD products, including immunology, molecular, and flow cytometry, dedicated to creating comprehensive clinical diagnostic solutions.

Rooted in the fertile ground of knowledge innovation at the Chinese Academy of Sciences, Biosino has always taken it upon itself to actively push forward the development of the national IVD industry. The company boasts a research and development team composed of numerous PhDs and Masters, has established an "enterprise post-doctoral research workstation," jointly established an in vitro diagnostic engineering research center with the country's highest-level research institutions in the life sciences field, and has conducted comprehensive cooperation with internationally renowned companies. Biosino has undertaken numerous national scientific and technological tasks, including the "863 Program", National Science and Technology Support Program, National High-tech Industrial Demonstration Project, and Knowledge Innovation Project of the Chinese Academy of Sciences, being recognized as an "Innovative Enterprise" in the national independent innovation demonstration zone.

Biosino has a 16.000 square meter production base constructed strictly according to GMP standards and has passed ISO9001, ISO13485, European Union CE, South Korea KGMP, and Canada CMDCAS quality management system certifications. It has been accredited by ISO/IEC 17025:2017 "General Requirements for the Competence of Testing and Calibration Laboratories" and is authorized to use the CNAS laboratory accreditation mark. Currently, the company has obtained 345 in vitro diagnostic reagent product registration certificates, mainly covering twelve categories of biochemical detection projects such as liver function, renal function, blood lipids, cardiovascular, diabetes, and rheumatism, making it one of the manufacturers with the most comprehensive range of biochemical diagnostic reagent products in China.

Biosino has over 500 agents and dealers, has established branches in most provinces across the country and overseas, and has built a nationwide marketing network and technical service support system. The company always adheres to the marketing strategy of simultaneous development in both domestic and international markets, involving domestic sales, international trade, innovative business, technical, and application support, achieving scientific marketing system capability building and channel layout. Over the years, the company's diagnostic products have maintained a leading position in the domestic market and continue to expand overseas, exporting products to over 60 countries and regions including Europe, North America, Africa, and Southeast Asia.

After fifty years of changes and perseverance through challenges, as a participant and promoter of the development of the national IVD industry, Biosino has always been committed to public health and innovation, leading the industry with excellent achievements. Bearing the corporate mission of "beautifying life with technology" and the vision of "becoming a leader in the IVD industry with international competitiveness," adhering to the corporate values of "being honest, putting others first", and upholding the spirit of "integrity, cooperation, dedication, innovation", Biosino focuses on the field of in vitro diagnostics, concentrates on innovation, and pursues lean management. Biosino will continue to accelerate the strengthening of its scientific and technological innovation capabilities and capacity building, continuously providing the IVD industry with more accurate and comprehensive solutions through new products, new technologies, and new models, contributing more and better Biosino power to global health!

Corporate Mission: To beautify life through technology.

Corporate Vision: To become a leader in the IVD industry with international competitiveness.

Corporate Values: Be honest and place integrity first.

Corporate Spirit: Integrity, cooperation, dedication, innovation.

Business Philosophy: Focus on the core business, build the industrial chain, and develop competitiveness.

Talent Philosophy: Believe in the future, embrace change, transform oneself, create value.

Quality Policy: High quality, efficiency, craft premium reagents; accurate, stable, measure vital functions.

RECOGNITION AND AWARDS



GOVERNANCE

During the reporting period, the company has consistently complied with all code provisions listed in Appendix C1 "Corporate Governance Code" of the "GEM Listing Rules" of the Hong Kong Stock Exchange and has adopted the recommended best practices listed there in where appropriate.

The company has established the "Biosino Bio-Technology and Science Incorporation Articles of Association" and, in accordance with the "Board of Directors Meeting Rules," "Shareholders' Meeting Rules," and "Supervisory Board Meeting Rules" and other system requirements, regularly convened shareholder meetings, board meetings, and supervisory board meetings for management decision-making and operational oversight. In this fiscal year, the company's decision-making and supervisory bodies, including the shareholders' meeting, board of directors, and supervisory board, have strictly managed decision-making and operational oversight in accordance with normative operating rules and internal systems. The board of directors convened 5 times, deliberating on 17 proposals in total; the shareholders' meeting was held twice, with a total of 10 proposals; the supervisory board convened twice, reviewing 2 proposals.

GOVERNANCE STRUCTURE

The company has established a governance structure composed of the Shareholders' Meeting, the Board of Directors and its special committees, the Supervisory Board, and the senior management team. The Board of Directors has established three committees: the Remuneration Committee, the Nomination Committee, and the Audit Committee, to oversee specific areas of the company's affairs.

BOARD DIVERSITY

On January 8, 2019, the Board of Directors adopted the "Board Member Diversity Policy," which specifies that the selection of Board members will be based on a range of diversity categories, taking into account the company's business model and specific needs. This includes, but is not limited to, gender, age, race, language, cultural background, educational background, industry experience, and professional experience. Currently, the Board consists of 2 executive directors, 4 non-executive directors, and 4 independent non-executive directors. In terms of educational background among the Board members, there are 4 with doctoral degrees, 5 with master's degrees, and 1 with a bachelor's or other degree. Regarding tenure as directors of the company, one director has served for more than 20 years, while the others have served for less than 5 years. The current 10 directors are professionals with extensive experience in fields such as biological sciences, risk management, accounting, and law.

Board Members:

- percentage with Doctoral Degrees: 40%
- percentage with Master's Degrees

or Higher: 90%



BOARD OF DIRECTORS' ESG STATEMENT

Biosino has established an ESG control structure covering three levels: decision-making level, management level and executive level. The Board is the decision-making level of ESG and the highest decision-making body of ESG. The ESG Committee of the board of directors is responsible for formulating the Company's ESG strategic policy, reviewing and making decisions on major ESG matters of the Company, regularly supervising and inspecting the progress of ESG related matters, fulfilling the ESG work requirements put forward by the Listing Supervision Department to the Board, and providing support for ESG decisions of the Board. At the same time, timely and accurately identifying the demands of various stakeholders, carrying out evaluation, and determining and revising material ESG issues. At the same time, we would discuss relevant issues, including but not limited to product quality, climate change, anti-corruption and other fields, and respond to the demands of various stake holders.

The chairman takes charge of the ESG Committee and is responsible for presiding over the work of the Committee. The Secretary of the Board and all senior executives of the Company form the ESG leading group to formulate the Company's ESG management system, monthly inspect the implementation of the Company's ESG work, and regularly report the work progress to the ESG Committee. All departments of Biosino dispatch a representative to form an ESG working group to implement the decisions of the management and be responsible for the implementation of ESG objectives.

The main responsibilities of the ESG Committee include:	Develop ESG vision, strategy and policy; monitor the implementation of ESG strategy; monitor expenditure of ESG work; supervise the company's external communication and dissemination; revi the annual ESG report and make recommendations to the board of directors for approval.
The main responsibilities of ESG management include:	Regularly carry out stakeholder communication, clarify the annual ESG focus, continuous improve and enrich the Company's ESG development strategy and development plan, a continuously follow up the implementation of ESG related matters valued by stakeholders.
The main responsibilities of ESG executive layer include:	Around the Company's mission and vision, take specific improvement measures on Company's compliance with business norms, green and low-carbon operation, prod technology innovation, promoting supply chain development, protecting employees' rights a interests and supporting social development to ensure the completion of the annual ESG goal.



INTERNAL CONTROLS AND RISK MANAGEMENT

The Board of Directors is responsible for maintaining an appropriate and effective internal control and risk management system to protect the interests of the company and its shareholders. It regularly reviews and supervises the effectiveness of the internal control and risk management systems to ensure they are comprehensive and adequate. The related internal audit functions performed by the Board include establishing formal arrangements for applying financial reporting and internal control principles in accounting and financial matters to ensure compliance with the Listing Rules and all relevant laws and regulations; the company appoints external consultants to review the areas defined by the Audit Committee. The existing organizational structure and close supervision by management, along with the appointment of external consultants, enable the company to maintain sufficient risk management and internal controls. The Board will from time to time review the necessity of establishing an internal audit function and may establish an internal audit team when needed. The company has developed related system documents such as the "Risk Management Control Procedures" and "Financial System Manual," which define the processes and methods for risk management.

Risk Identification

The company regularly organizes meetings to discuss financial, operational, compliance control, and risk management processes. At the same time, it hires independent external auditing institutions, and third-party professional companies assess the risks faced by the enterprise and the response measures to ensure that effective measures have been taken to identify existing and potential risks, including compliance risks, operational risks, and business continuity risks, and further clarify the priorities of risk management based on the potential impact and likelihood of risks.

Specialized Risk Training and Dissemination

To enhance employees' awareness of compliance and risk management, the company regularly conducts diversified specialized risk training and dissemination for all employees, covering key areas such as compliance, information security, product quality, and ESG, to ensure that all employees are fully aware of internal compliance and risk control policies and procedures. During the reporting period, the company conducted more than 90 training sessions on laws and regulations, risk management, anti-corruption, ESG, etc.

Risk Reporting Mechanism

On the basis of the whistleblowing mechanism, the company has set up a suggestion box (yijianxiang@zhongsheng.com.cn) to encourage employees to proactively identify risks related to business ethics and report any identified risks to the company.

BUSINESS ETHICS AND ANTI-CORRUPTION POLICY

Biosino issued the anti-corruption policy to fully support and uphold the high standards of integrity, honesty and fair competition in carrying out the Company's business, and will never tolerate any form of bribery or corruption. The policy clearly states that employees should abide by all applicable anti bribery laws, especially the Hong Kong bribery Prevention Ordinance, the British Anti Bribery Act, the People's Republic of China ("PRC") Criminal Law and the PRC Anti Unfair Competition Act, and common law relating to crimes to avoid misconduct of public officials. The Company regularly provides anti-corruption training and briefings for all employees. The training courses include online courses and on-site demonstrations. The Company actively encourages employees to report any concerns about bribery and corruption. All business departments keep records of suspected and actual accidents, and report relevant statistics to the financial controller of the Company on a quarterly basis. During the Reporting Period, there was no corruption incident in the Company.

The Board of Directors is responsible for the implementation of anti-bribery and anti-corruption efforts within the group. The executive directors of the company are responsible for ensuring the effective implementation and monitoring of any significant bribery or corruption activities within the group. During the reporting period, Biosino launched two specialized training sessions on anti-commercial bribery and legal regulations, sharing the training materials with all employees. The training content mainly included the definition of commercial bribery, forms and common misconceptions of commercial bribery, liability and risk control in commercial bribery.

Biosino maintains an open, trusting, and respectful atmosphere. It issued a "Notice on Initiating Opinion Collection Work," setting up three methods for reporting and collecting opinions. Employees can provide anonymous feedback or reports through a suggestion box, email (email address: yijianxiang@zhongsheng.com.cn), or directly to the company's supervisor and worker representative Ren Junhe. If confidentiality is required, the company's supervisor Ren Junhe will keep the information confidential. Once a report is received, management will take timely action to ensure that no whistleblower will suffer discrimination, unfair treatment, or retaliation, thereby protecting whistleblowers to the greatest extent.



BUSINESS INFORMATION SECURITY

Biosino strictly adheres to relevant laws, regulations, and the rules of the Hong Kong Stock Exchange, as well as the company's internal "Articles of Association" and "Information Disclosure System." The company has diligently fulfilled its information disclosure responsibilities as a listed company. Biosino ensures that all publicly disclosed information is timely, fair, true, accurate, and complete, to guarantee that all investors have equal and timely access to relevant company information. During the reporting period, the company did not find any information that should have been disclosed but was not disclosed in a timely manner.

The governance of Biosino does not have significant differences from the requirements of the China Securities Regulatory Commission and the Hong Kong Stock Exchange. The company will continue to consolidate and further improve its governance level, enhance corporate competitiveness, and thereby return better operating results to our investors. Biosino places great emphasis on the protection of customers' trade secrets, data information, and personal privacy. Through strict internal control processes, we have achieved the security and controllability of information collection, processing, and transmission. Biosino strives to implement the security of business information in every aspect of serving our customers. We strictly comply with laws, regulations, policies, and industry standards related to customer privacy protection. New employees sign a confidentiality agreement upon joining the company, agreeing to confidentiality obligations during and after their employment.

Biosino accepts audits from customers on the company's data security, data center management, and general control processes to ensure risks are maintained at a controllable level. In response to cybersecurity issues, the company has established complaint and reporting channels, allowing all employees to report through a suggestion box, email (email address: yijianxiang@zhongsheng.com.cn), or directly to the company's supervisor and worker representative Ren Junhe. During the reporting period, there were no significant cybersecurity incidents or commercial information leaks.

STAKEHOLDER IDENTIFICATION

It is confirmed that in combination with the Company's own business characteristics and drawing on the experience of its peers, the main stakeholders of Biosino include: shareholders and investors, customers, employees, the Board and management, suppliers and partners, regulators and the government, as well as local society, non-governmental organizations and the media. Biosino can fully respect the legitimate rights of stakeholders and actively cooperate with them on the basis of fairness, rationality and mutual benefit to jointly promote the sustainable and healthy development of the Company. This year, we communicated with stakeholders in many ways through online and online meetings, face-to-face interviews, questionnaire, etc.

Compliance operation General meeting of shareholders Information transparency Timely release, on the information disclosure Return on investment website Improve product and service quality Roadshows and public events Risk management Corporate governance Setup telephone, email and other communication channels Market position Stable relationship Service visit Customer service quality Satisfaction survey product training Protect customer privacy Telephone Business integrity and ethics Wechat Health and safety Email Satisfaction survey Development and training Occupational health and safety Signing agreements Compensation and benefits Hold meetings Employee care Discussion Employee communication Organizing activities the Board of Directors Compliance operation Holding a meeting and Management Anti corruption Online communication Talent retention Enterprise sustainable development Supplier meetings Wechat Fair bidding ■ Field investigation ■ Email real-time Business ethics and reputation ■ Singing the contract ■ Communication Long term cooperative relationship Telephone Compliance with regulations Accept inspection and research Regulators Fill out a form Policy implementation Pay taxes Assist in review Responding to national strategies NGO and Media ■ Give back to society Exchange, interview and contact Environmental protection Community activities Social welfare Health and safety

Biosino is able to fully respect the legitimate rights and interests of stakeholders such as product users, creditors, suppliers, employees, and communities. We will actively cooperate with them on the basis of fairness, reciprocity, and compliance with laws and regulations, to promote the sustainable and healthy development of our company.

The company strictly follows the procedures specified in the "Articles of Association" for appointing supervisors. The supervisory board is composed of three members, two of whom are representatives nominated by shareholders, and one is an employee representative elected by the staff representative assembly. The company's supervisory board can independently and effectively exercise the rights of supervision and inspection over directors and senior management. The supervisory board regularly convenes meetings and holds special meetings as needed in a timely manner.

MATERIALITY ASSESSMENT

In accordance with the "Environmental, Social, and Governance (ESG) Reporting Code" of the Hong Kong Stock Exchange, and taking into account both internal and external stakeholders' assessment of potential issues listed, as well as the business attributes of Biosino, the company identified 24 significant issues related to its business. It invited stakeholders such as employees, customers, suppliers, and company executives to participate in both online and online surveys, to score and rank these potential significant issues. Finally, based on the survey results, the company revised and supplemented the content of the significant issues and created a significance issue matrix.

Materiality assessment



PRODUCT RESEARCH AND DEVELOP MENT

Category	High Importance Issue	s Medium Importance Issues
Corporate Governance	 Risk Management Corporate culture and Employee Relations Management Business Information Security The Importance of Bio Safety in the IVD Field ESG Governance 	 Supply Chain ESG Management Business Ethics and Anti-corruption Internal Control and Supervision Responsible Marketing
Product Innovation	Technology and InnovationProduct and Service Quality	 Intellectual Property Protection
Green and Low-Carbon	Emissions ManagementResource Consumption Management	 Energy Management Environmental Management System Climate Change Mitigation and Adaptation
Employee Development	Talent Development and RetentionEmployee Rights and Benefits	Occupational Health and SafetyDiversity and Equality
Giving Back to Society		 Health Promotion and Inclusivity Industry Development and Win-win Cooperation Community and Philanthropy

Importance. When the issues related to ESG will have a significant impact on investors and other equity holders, they need to be disclosed in the report.

Quantification. Make the key performance indicators measurable so that the benefits of ESG management system can be evaluated and verified.

Balance. The ESG report presents the performance of the issuer in an impartial manner to avoid the possibility of improperly afecting the decision-making or judgment of the readers.

Consistency. This report adopts the same data disclosure method as in previous years, without comparing data from different years, and includes changes in statistical methods and key performance indicators.

PRODUCT RESEARCH AND DEVELOPMENT AND INNOVATION

HEALTHCARE INCLUSIVITY

Benefiting the Public Through Centralized Procurement

Since the implementation of the national policy for bulk purchasing of biochemical diagnostic reagents, Biosino Bio-Technology and Science Incorporation, a high-tech enterprise nurtured by the Institute of Biophysics of the Chinese Academy of Sciences, has always adhered to the principle of prioritizing national interests and has taken on the national mission by actively participating in centralized procurement work. The company, through technological innovation, lean production, and cost reduction and quality improvement strategies, effectively ensures product quality and market competitiveness. In product development, quality improvement, cost control, and application services, Biosino, with its nearly half-century of profound accumulation and continuous innovation in the field of biochemical diagnostics, demonstrates a development trend that keeps pace with the times.

Aiming to reduce patients' financial burdens and lower healthcare costs, the company actively responds to the national healthcare reform. In the national centralized procurement of biochemical diagnostic reagents, Biosino stands out with its superior product performance and efficient cost control capabilities. In the centralized volume-based procurement round of biochemical test reagents for renal function and myocardial enzymes in the provincial-level alliance in 2024, 23 product specifications submitted by Biosino entered Group A. This is another achievement with outstanding performance for Biosino to repay society and the market after the liver function centralized procurement last year. It demonstrates the technical advantages of Biosino's historical brand in the field of biochemistry. At the same time, it also shows the market's support and recognition for the national IVD brand! A total of 211 manufacturers participated in the quotation for this round of centralized procurement. Biosino once again stood out among the fierce competition.



The company follows the ethical principles of the Declaration of Helsinki by the World Medical Association and the national requirements for the ethics of biomedical research involving humans. In the development process of in vitro diagnostic reagents, it strictly adheres to the "Regulations for the Registration and Record Management of In Vitro Diagnostic Reagents," "Quality Management Standards for Medical Device Clinical Trials," "Technical Guidelines for Clinical Research of In Vitro Diagnostic Reagents," and relevant laws and regulations to ensure our R&D activities are both innovative and responsible, prioritizing the rights, safety, and health of research subjects above scientific and social interests

During clinical research, we consider the acquisition of trial samples and the risk of trial results to subjects, seeking ethical committee review to ensure that the trial does not expose subjects to unreasonable risks. Before the trial, clinical trial protocols, informed consent forms, and other relevant documents are submitted to the medical ethics committee of the hospital where the clinical trial responsible unit is located by the hospital's clinical trial management department, and clinical trials can only begin after obtaining approval from the ethics committee. If it is objectively impossible to obtain informed consent from research subjects or the study uses patients' residual samples from routine diagnostic and treatment processes without any contact with the patients, posing virtually no risk to the subjects, exemption from informed consent may be granted after review and approval by the ethics committee. Research testing results are only used for product registration applications, with no link between results and individual patient identity information, and no test reports sent to patients. There is no harm to the rights, safety, or privacy of research subjects. Through these measures, our company is committed to reflecting high ethical standards in the R&D process to protect the rights and welfare of participants while advancing medical science.

ECOLOGICAL CO-CONSTRUCTION

Responsible Marketing

The company makes every effort to identify and reduce potential compliance risks caused by improper marketing practices, strictly adhering to the laws, regulations, and industry standards related to marketing in the operating locations. The company regularly provides specialized training on responsible marketing to all employees related to marketing positions, including laws and regulations, internal rules and regulations, and product knowledge. Training is conducted both online and online to help marketing personnel understand the group's regulations related to marketing, ensuring they promote and sell products and services reasonably and compliantly. A material review and supervision procedure has been established based on responsible marketing principles, with all marketing materials requiring approval from authorized company personnel before release.

During the reporting period, the company did not experience any incidents violating product and service information and labeling regulations and/or voluntary codes, nor did it have any violations related to marketing communication (including advertising, promotion, and sponsorship) regulations and/or voluntary codes.

TECHNOLOGY AND INNOVATION

The company has established a project-centric performance evaluation system, shifting the focus of R&D center management from project process control to the initiation and acceptance of outcomes

Since pioneering China's enzymatic mono and dual biochemical reagents, Biosino has been guided by the need to meet public welfare demands and taken it upon itself to promote the development of the national IVD industry. The company emphasizes investment in technological R&D, actively carries out technological innovations, perfects the intellectual property protection system, fully leverages the advantages of its proprietary intellectual property, and insists on continuous independent innovation. It has established multiple research platforms, including enzymatic reaction systems, chemical reaction systems, reference materials, immunological detection methods, genetic diagnosis technologies, clinical rapid diagnosis, and flow cytometry. The company boasts a 78member R&D team, a 3,000 square meter R&D center, and advanced diagnostic equipment.

On February 1st, Biosino's fully automatic sample processing system was certified and launched.

On March 18th, Biosino's new product "KingKong 9000" intelligent laboratory assembly line made a dazzling debut in Chongqing, the city of mountains, and was grandly released. For Biosino, the release of this assembly line is not only a display of past technical accumulation, but also a clear indication of future development direction. Relying on advanced intelligent control systems, flexible production line layouts, and efficient production capabilities, KingKong 9000 will lead laboratories into a brand-new era.

On August 21st, Biosino's oficially release the fully automated flow workstation at the Hangzhou exhibition.

On September 3rd, Biosino's SinoCyteX Scientific Flow Cytometer Honored with Nomination for the '3i Award - Outstanding New Scientific Instrument. On April 7th, 2024, the signing and unveiling ceremony of the joint laboratory for industry-university-research collaboration jointly established by the East China Industry Research Institute of Life Sciences of Peking University and Biosino Precision Medical Laboratory was grandly held in Hefei.





In 2024, the linear upper limit of the company's β2-microglobulin determination kit (latex immunoturbidimetric method) product line has been raised, enabling the detection of both serum and urine samples simultaneously. The company's homocysteine determination kit (enzyme cycling method) adopts the cystathionine method and has a relatively low reagent cost. The self-produced flow cytometry reagents of Biosino's platelet project have been certified for market launch. The high-end (research) flow cytometer SinoCyte X with 4 lights and 21 colors from Biosino has been approved for market launch.

Intellectual Property Protection

The company continues to increase R&D investment, continuously improves technology and production processes, focuses on product quality system construction, is committed to extending product lifecycles, reducing costs, and providing safer and more effective products and services. To protect related intellectual property, the company's R&D personnel write patent applications for the products developed.

On the path of insisting on independent innovation, Biosino continues to deepen product reforms, focusing on strengthening the protection and application of intellectual property, accelerating product innovation, and promoting outcome transformation. To date, the company has obtained 156 authorized patents, including 85 invention patents, 60 utility model patents, and 11 design patents; obtained 26 software copyrights, a total of 35 trademarks, and published 48 papers.

Access to intellectual property

RMB million yuan



Registered Products

The group company currently holds a total of 345 medical device registration certificates. Among them, 274 are held by the parent company, 24 by Biosino Gene, and 47 by Biosino Suzhou. In 2025, the company will carry out the registration of other new products to ensure its leading position in the registration certificates.

The company's products mainly cover 12 categories of biochemical tests including liver function, kidney function, blood lipids, cardiovascular, diabetes, rheumatism and so on, totaling 114 projects. Among them, there are 21 items for liver and pancreatic function, 13 items each for kidney function and nutritional ions; myocardial, cardiovascular, and special protein categories each have 11 items; diabetes and composite class calibration quality control each have 9 items; rheumatic inflammation and tumors each have 7 items; blood coagulation has 3 items; and pancreas has 3 items.



Number of Medical Device product Registrations by Enterprises (within validity period)

BIOSINO Biotech Co., Ltd. Registered Quantity





The classification and distribution map of biochemical diagnostic reagents, total number: 114 (Category name, number of items, percentage in the total)





Hepatic and Pancreatic Function	Renal Function
Myocardium	Cardiovascular

- Special Protein Category
- Diabetes Mellitus
- Rheumatic Inflammation Blood Coagulation
- Composite Category Tumor

Nutritional Ion Category

Pancreas

PRODUCT AND SERVICE QUALITY

As one of the largest industrial bases of medical biochemical diagnostic reagents in China, Biosino adopts international advanced management mode to realize advanced production processes such as microcomputer networking and automatic connection, and the production environment is fully closed, clean and automatic temperature control. At the same time, in strict accordance with the standard requirements of ISO 13485:2016, quality management personnel, quality control personnel and production operators with strong sense of responsibility and excellent technology are equipped to monitor the whole production process, and a perfect and strict quality control system is established. Quality control is carried out in the production process to ensure the repeatability and stability within and between batches of products; By participating in the inter room quality assessment activities of the National Health Commission of the People's Republic of China and Beijing authorities, the accuracy of the products can meet or exceed the standard requirements. During the Reporting Period, the Company did not return products for safety and health reasons. Because the products sold by the Company do not reach consumers directly, it does not involve the protection of consumer data and privacy policies. During the reporting period, the company had no products returned for safety and health reasons; since the company's products did not reach consumers directly, there were also no issues related to the protection of consumer data and privacy policies. In order to promote partners to continuously improve their quality management level, the quality manual formulated in 2009 is revised and improved every year according to the requirements of laws, regulations and quality management system.

Commission Clinical Inspection Center.





The highest rank supervisor of the Company's quality management system is the president. In order to ensure the establishment, implementation and effectiveness of the Company's quality management system, the Company promises:

Establish the guiding ideology of "focusing on customers" among all employees and translate it into the specific requirements of the Company;

- Formulate quality policy;
- Formulate quality objectives;
- Conduct management review regularly;
- Ensure the availability of resources and continuously improve the effectiveness of the quality management system.

PRODUCT RESEARCH AND DEVELOP-

GREEN AND LOW-CARBON TALENT DEVELOPMENT DEVELOPMENT

ECOLOGICAL CO-CONSTRUCTION

ECOLOGICAL CO-CONSTRUCTION

Quality Management System

As a manufacturer of IVD, Biosino establishes, implements and maintains a guality management system and maintains its effectiveness in accordance with the requirements of ISO 13485:2016" Medical Device Quality Management system Requirements for Regulations" and "Medical Device Production Quality Management specifications".

Quality policy

High quality efficient innovative premium reagent products accurate, stable, detect life functions

As a manufacturer of in vitro diagnostic reagents, Biosino determines the required processes, including those related to management responsibilities, resource management, product realization, measurement analysis and improvement; the risk management control procedure is established and implemented to manage the process throughout the product life cycle. The sequence and interaction of the processes are clearly defined.

Document structure of quality management system



In 2005, Biosino was the first to establish a microcomputer managed automatic production line in China and built a new plant in strict accordance with GMP standards. At the same time, in order to ensure the stability of product quality, the Company is equipped with international leading full-automatic biochemical analyzers such as Hitachi, Beckman and Abbott. It has automatic filling and plugging linkage machine, three head screw sub packer, freeze dryer and other automatic production equipment. Pure water treatment system and ultra pure water device are introduced. Combined with advanced production technology and management means, it provides strong technical support for the all-round compliance of clinical diagnostic reagents of Biosino.



Safety and Quality System Certification

Biosino has obtained a series of safety and quality management system certification, laboratory accreditation and other certificates:

Three level review certificate of enterprise safety production standardization issued by the state Emergency Management Bureau;





■ ISO13485:2016 Medical Device Quality Management system Certification



Since its establishment in 1988, Biosino has placed great emphasis on technology research and development and innovation, continuously improving its management and technical capabilities, and strictly controlling product quality, always striving for innovation and excellence. Biosino has once again successfully passed the qualification review and regular review of the China National Accreditation service for Conformity Assessment (CNAs), indicating that its calibration and testing services have been upgraded and its management and technical capabilities have been recognized by the state, demonstrating the company's comprehensive strength in the industry.

ISO / IEC 17025:2017 General requirements for the competence of the laboratories in testing and calibration.

<text><text><text><text><text><text><text><text></text></text></text></text></text></text></text></text>	A da da fir para a fir fir da
--	---

Service Guarantee

Biosino pursues the purpose of "technical service first", and has set up a technical service department to appoint high-quality talents majoring in inspection, pharmacy, medicine and marketing to conduct regular market patrol research and user follow-up. By holding training courses, holding academic exchanges, regularly publishing the bulletin of laboratory medicine technology, and combining with online interaction, we can provide users with professional technical support and services, and solve various difficult problems in product application on site. We also endeavour to provide customers with the best service at the first time.

The Company has established and implemented the customer feedback management procedure to standardize the customer complaint handling process in accordance with applicable laws and regulations, clarify the responsibilities of each department, and clarify the timeliness and effectiveness of customer complaint handling. The quality management department shall keep complaint handling records. The record includes:

- Receiving and recording information;
- Evaluate the information to determine whether the feedback constitutes a complaint:

PRODUCT RESEARCH AND DEVELOPMENT

- Investigate complaints:
- Determine whether information needs to be reported to the appropriate regulatory authorities;
- Dispose of products related to complaints;
- Determine whether corrective actions need to be initiated or not

In 2024, there were no complaints regarding product quality. There were 6 cases of returns due to product packaging damage and leakage in individual products, and the returned products were disposed of as scrap.

The Company has simultaneously established and implemented the control procedure for adverse event monitoring and re-evaluation of medical devices, carried out adverse event monitoring and re-evaluation, and reported major quality accidents or advisory notices to relevant regulatory authorities. The quality management department shall keep records of reports to the regulatory authority.

In addition, the Company has established and implemented the product monitoring and measurement control procedure to monitor and measure the characteristics of products to verify that the product requirements are met. For the control of nonconforming products, the company has established and implemented the nonconforming product control procedure to ensure the identification and control of nonconforming products to prevent unexpected use or delivery ...



GREEN AND LOW-CARBON DEVELOPMENT

Biosino attaches great importance to environmental protection, emphasizes the importance of environmental protection to corporate social responsibility and sustainable development, and actively promotes the construction and implementation of environmental protection management system. Biosino attaches great importance to environmental protection, emphasizes the importance of environmental protection to corporate social responsibility and sustainable development, and actively promotes the construction and implementation of environmental protection management system.

ENVIRONMENTAL PROTECTION POLICIES AND OBJECTIVES

From the strategic perspective of environmental and social sustainable development, Biosino strictly controls pollution, promotes energy conservation and emission reduction, protects the ecological environment, and strives to create an environment-friendly business community. During project screening, the Company focuses on its potential impact on the environment, attaches great importance to environmental protection, ensures the environmental impact compliance and compliance of Biosino's business activities, actively enables the wide application of advanced environmental technology in the Company's business activities, reduces resource consumption, and advocates the attention of all stakeholders to environmental protection.

During the Reporting Period, the Company and relevant departments carried out full coverage inspection on the environmental management status of all holding subsidiaries, promoted the improvement of environmental management of holding subsidiaries, and completed the construction and implementation of management system within a time limit, so as to effectively ensure the sustainable development of the enterprise. During the Reporting Period, Biosino, its subsidiaries and joint-stock enterprises did not have any environmental pollution incidents.



ADDRESSING CLIMATE CHANGE

As the first enterprise in the IVD field to propose a "dual carbon" goal, Biosino actively responds to the climate change initiative of the Paris Agreement and China's "dual carbon" strategic objectives. The company identifies climate change-related risks and opportunities and refers to the International Sustainability Standards Board (ISSB)'s "IFRS Sustainability Disclosure Standard S2-Climate-related Disclosures (Exposure Draft)" to disclose relevant information about the company's climate change risk management.



The company's board of directors and ESG committee are responsible for regularly reviewing the execution of climate change-related matters in the ESG report, supervising the implementation of the "carbon reduction" targets, promoting energy structure adjustment, improving equipment energy efficiency, advocating for office energy saving, and collaborating with suppliers to reduce carbon emissions in the supply chain.

0 Goals

Our company has set strategic "dual carbon" goals to achieve carbon peak by 2028 and carbon neutrality by 2050. In terms of supply chain management, suppliers of enzymes, antigens antibodies, packaging materials, and cold chain logistics have been invited to participate in ESG training and audits. We require Class A logistics suppliers to provide carbon emission data and information. The supplier self-assessment process now includes the requirement to conduct carbon assessments Since the smart distribution rooms at the company headquarters were put into operation, they have been running safely and stably, saving 200,000 yuan in electricity costs this year. Additionally, the company's HR department has intensified efforts in localized recruitment to address local employment needs. With employees now working closer to home, low-carbon commuting has been promoted. By consolidating two shuttle buses into one, energy consumption has been further reduced. Through these practical actions, we are gradually progressing towards our "dual carbon" goals.

Biosino's "Dual Carbon" Goals: Achieve carbon peak by 2028 and carbon neutrality by 2050.



Employee participation is key to achieving our emission reduction targets and implementing our climate change adaptation plan. The company proactively offers training courses, lectures, and other internal communication channels to raise their awareness in addressing climate change. Biosino invites ESG experts to conduct ESG training for the company's supplier representatives and leaders, Biosino executives, and heads of various departments. The training content includes the development history of ESG concepts, international and domestic policy trends, and corporate case studies in the ESG field.



In 2024, Biosino mainly adopts the carbon emission factor method to account for the company's greenhouse gas emissions based on the "Greenhouse Gas Accounting System: Enterprise and Reporting Standards (2004)", while referring to ISO 14064-1:2018 "Norms and Guidelines for Quantification and Reporting of Greenhouse Gas Emissions and Removals at the Organizational Level", "Methods and Reporting Guidelines for Greenhouse Gas Emissions of Other Industrial Enterprises", and the requirements of the Chinese Ministry of Ecology and Environment. From the perspective of the company's main sources of carbon emissions, the company's direct emissions (Scope 1) mainly come from the operation of its own vehicles and refrigerant escape emissions; Indirect emissions (Scope 2) mainly come from electricity and steam used in factories and office buildings.



The formula for calculating the carbon emissions from the operation of self-owned vehicles is: Emissions = Gasoline Consumption (liters) × Regional Power Grid Emission Factor (kgCO₂e/liter). In 2024, the gasoline consumption of the self-owned vehicles of Biosino (including all its branches) was 38,384 liters. According to the data queried from the IPCC emission factor database, the carbon emission factor of gasoline during vehicle driving is 2.31 kgCO₂e/liter.

Calculated according to the formula, the annual carbon emissions of the self-owned vehicles amount to 88.67 tCO₂e.



The company integrates climate change risks into its comprehensive risk management framework, including the identification, assessment, and management of climate change risks. Based on scenario analysis of ISSB-2, the company combines industry characteristics, operational location policy orientation and geographical features, and historical records of extreme weather to identify a significant list of climate risks related to the company, promoting the implementation of climate change risk management across the entire value chain. In the short term, the company will conduct risk assessments and financial forecasts; in the medium term, it will develop plans that align with policy trends, market development, and customer demands; in the long term, it aims to achieve the goal of carbon neutrality.

Significa	ant Climate	Change Risks	Relevance Explanation
Discost	Chronic Risks	Increase in average temperature	The production workshops for reagents have high temperature requirements. In the scenario of global warming, the company anticipates an increase in energy consumption to maintain normal production operations, further increasing operational costs. Additionally, a rise in temperature leading to more frequent hot weather exacerbates health risks for employees.
Physical Risks	Acute Risks	Increased frequency of extreme weather events	Global warming causes instability in the climate system, making extreme weather events more frequent and severe, which poses challenges to the company's operational stability. Moreover, the costs associated with addressing these extreme weather events contribute to increased operational costs.
Transition Risks	Policy and Legal Risks	Requirements and regulations for existing products and services	Governments are improving carbon emissions trading and management systems to meet the goals of the Paris Agreement. This could lead to increased costs of greenhouse gas emissions through carbon taxes or higher fuel and electricity prices. As more industries are included in the carbon emissions trading system, the company may face higher operational costs.
	Technological Risks	Upfront costs of transitioning to low-emission technologies	In response to government "dual carbon" policies and stakeholder expectations, the company will advance research in low-carbon technologies and optimize energy structure to reduce carbon emissions and improve energy efficiency, which will result in increased operational costs.
	Market Risks	Rise in raw material costs	Climate change can affect the quantity and stability of raw materials, with a reduction in supply leading to increased costs.
	Reputational Risks	Stakeholders' growing concern over negative feedback	Global warming and the accompanying impacts of climate change have attracted increasing attention from corporate stakeholders. Therefore, they have higher expectations for the actions companies take in addressing these challenges.

Risk Management

To proactively address the identified climate change risks, our company has developed "adaptation" and "mitigation" strategies to manage climate change risks effectively.

Adaptation	Our company enhances its response to new government policies by regularly inspecting the electrical systems, steam
Strategies	strategies systems, drainage systems, and electrical instruments, as well as conducting regular inspections of outdoor
	factory facilities.
	Continuous investment in equipment renewal and optimization is also a priority.
Mitigation Strategies	Our company continuously updates refrigeration equipment, including compressors and condensers, by establishing smart distribution rooms and steam automatic operation and maintenance systems. This approach not only saves on electricity
Strategies	and steam costs but also achieves energy savings and emission reduction.

2

The Carbon Emissions from the Escape of Refrigerants

The formula for calculating the carbon emissions from the escape of refrigerants is: Refrigerant escape amount × Global Warming Potential (GWP).

In 2024, the refrigerant escape amount of Biosino (including all its branches) was 30 kg, among which the amount of R507 refrigerant was 10 kg and the amount of R22 refrigerant was 20 kg. According to the data queried from the IPCC emission factor database, the Global Warming Potential (GWP) of R507 is 3985, and the Global Warming Potential (GWP) of R22 is 1810. Therefore: Carbon Emissions = $(10 \times 3985 +$ 20×1810) kg CO₂e = 76.05 tCO₂e.

The Carbon Emissions from Purchased Electricity 3

The formula for calculating the carbon emissions from purchased electricity is: Emissions = Purchased electricity volume (kWh) × Regional power grid emission factor (kgCO₂e/kWh).

Among them, the provincial emission factor adopts the latest provincial or regional power grid emission factor released by the Ministry of Ecology and Environment of China.

As can be seen from the power purchase agreement, in 2024, a total of 1,304.264 kWh of electricity (including the electricity consumption for the transformation of Sino-German BGI's scientific and technological achievements) was purchased from State Grid Beijing Changping Power Company. Biosino Jinyu does not have the latest electricity purchase contract document, but since Biosino Jinyu and Biosino are both in Changping District, Beijing, it is reasonably inferred that the company's electricity comes from the Beijing power grid. The company's electricity consumption in 2024 was 447,200 kWh. The emission factor of the Beijing power grid is 0.558 kg CO₂e/kWh.

As can be seen from electricity bill, in 2024, Biosino Anhui purchased a total of 42,000 kWh of electricity from State Grid Anhui Power Grid. The emission factor of the Anhui power grid is 0.6782 kg CO₂e/kWh. In 2024, Biosino Suzhou does not have the latest electricity purchase contract document, but since the company is in Suzhou, it is reasonably inferred that the company's electricity comes from the Jiangsu power grid. The company's electricity consumption in 2024 was 95,000 kWh. The emission factor of the Jiangsu power grid is 0.5978 kg CO₂e/kWh.

Table: Carbon Emissions of Biosino in 2024- Overview

	Purchased Electricity Volume (kWh)	Emission Factor (kg CO ₂ e /kWh)	Emission $(t CO_2 e)$
Biosino*	1304264	0.558	727.78
- Biosino Jinyu	447200	0.558	249.54
- Biosino Anhui	42000	0.6782	28.48
- Biosino Suzhou	95000	0.5978	56.79
-	Total		1062.59

Note: The electricity consumption for Biosino technology transfer is included in the electricity consumption of Biosino.

The Carbon Emissions from the Purchased Steam 4

The formula for purchased steam is:

Emissions = Steam consumption × Calorific value × Emission factor.

The calorific value of steam is derived from the National Standard for Steam Enthalpy Value, and the emission factor is from the National Greenhouse Gas Emission Factor Database. According to the agreement with Beijing Yong'an Heating Co., Ltd., in 2024, Biosino (including Biosino Jinyu and Biosino technology transfer) purchased a total of 460t of steam from Beijing Yong'an. According to the introduction on the website of Beijing Heating Co., Ltd., all the boilers used by the company are gasfired boilers, so the emission factor of gas-fired boilers is adopted. According to the agreement with Beijing Heating Co., Ltd., the steam is used for both production and heating. Therefore, it is reasonably assumed that the steam used is low-pressure steam, and the calorific value data of low-pressure steam is adopted. The carbon emission factor of gas-fired boilers is 56.1 tCO₂e/tJ, and the calorific value of low-pressure steam is approximately 0.0028 tJ/t. Calculated according to the formula, the annual carbon emissions from steam are approximately 72.26 tCO₂e.

Greenhouse Gas Emission summary for Biosino During the Reporting period

Scope 1: The direct greenhouse gas emissions generated by emission sources owned or controlled by Biosino and its subsidiaries amounted to 164.72 tCO₂e, primarily including emissions from the operation of owned vehicles and refrigerant leakage.

Scope 2: The indirect greenhouse gas emissions generated from the electricity and steam purchased by Biosino and its subsidiaries amounted to 1134.85 tCO₂e, primarily including emissions from electricity and steam usage in factories and office buildings.

LOW-CARBON OFFICE

Since October 2022, Biosino has vigorously advocated for paperless office practices since adopting the OA (Office Automation) system, significantly reducing tree felling and carbon emissions while also enhancing information management efficiency, reducing office costs, and facilitating daily work for employees. We have integrated various work processes, including instant messaging, email, announcements and notifications, attendance management, administrative office work, process center, public filing cabinets, and mobile office functionalities. Additionally, all tasks, including those related to human resources modules and financial approvals, are processed through OA's online approval workflows. In 2024, the process center approved over 20,000 workflows, resulting in an approximate carbon reduction of 5 tons of CO₂e.





Greenhouse Gas Carbon Reduction

Establishment of the "Employee Low-Carbon Behavior Code"

Biosino, based on the "Low Carbon Office Evaluation" group standard, has reviewed its office carbon footprint, established, and implemented the "Employee Low-Carbon Behavior Code" to regulate employee behaviors towards energy saving and improved resource utilization efficiency.

Smart Distribution Rooms

The smart distribution room renovated at the company's headquarters in 2024 performed well in 2024, saving approximately 200 thousand yuan in annual electricity costs, about 250,000 kWh, and reducing emissions by approximately 140 tons of CO₂e.

EMISSION MANAGEMENT, THE UTILIZATION OF **RESOURCE AND ENERGY**

Emission Management

As the Company is mainly engaged in the production, sales and distribution of IVD reagent products, the business does not produce or discharge nitrogen oxides, sulfur oxides and other pollutants regulated by Chinese national laws and regulations. The Company entrusts a third-party organization to uniformly dispose of the generated hazardous waste on a regular basis. On the premise of ensuring the safety of hazardous waste storage, transportation and disposal, Biosino realizes the reduction of hazardous waste by standardizing the behavior of employees and raw material substitution. In addition, the production of emissions is reduced through the design of products that reduce the generation of waste liquid.

Pollutant Emission Classification:

- Sewage: it is composed of industrial sewage and domestic sewage. Main types of pollutants: five-day chemical oxygen demand, chemical oxygen demand, ammonia nitrogen, suspended solids and oils.
- Atmospheric emission: vehicle exhaust, etc
- Solid waste consists of hazardous waste and general waste. Hazardous wastes include chemical raw materials used in the production process, acids, alcohols, etc. and medical wastes generated in the laboratory. General wastes include recyclable wastes, such as packaging materials and domestic garbage generated by office.

Biosino strictly abides by relevant laws and regulations and relevant standards for the discharge of waste gas, wastewater and waste in the place of operation.

Measures to control pollutant emission:

- After the sewage treatment and pretreatment and reaches the standard, it will be discharged into the back-end secondary sewage treatment plant or the municipal sewage pipe network.
- The traffic exhaust gas is used in compliance with national standards.

• Each holding subsidiary should carry out the final compliance disposal through the professional organization with disposal qualification approved by the local environmental protection bureau, and carry out incineration, landfill or reprocessing and utilization in accordance with the regulations.

To reduce water consumption, the company has taken the following specific measures:

any abnormal water usage situations and take measures to ensure continuous improvement in water use efficiency. • Summer Central Air Conditioning System: Our company's air conditioning cooling system uses water recycling technology, greatly reducing the consumption of cooling water.

· Application of Water-Saving Devices: The company has installed water-saving devices such as efficient faucets at all water points, effectively reducing the waste of domestic water. In addition, the company uses a single piping system for heating and cooling, switching between summer and winter seasons through valves, to realize the recycling of water for heating and cooling, effectively saving water.

• Regular Maintenance: To ensure the efficient operation of the water system and reduce the loss of water resources, the company regularly inspects and maintains water facilities and pipelines. By promptly identifying and repairing issues such as leaks and drips, we minimize water loss.

Uni Use of water resources cubic m Power consumption kwh Steam ton Solid waste ton Hazardous waste ton

* Due to the diversity of product models, it's impossible to individually account for each product's energy and water consumption, making it dificult to calculate the specific energy and water consumption density of each product.



In 2024, Biosino utilized various types of packaging materials for its finished products, primarily consisting of rubber, glass, plastic, and paper products. The consumption details include 85.3 tons of glass bottles, 55.0 tons of plastic bottles, 1.0 tons of rubber stoppers, 3.5 tons of aluminum caps, 18.0 tons of packaging boxes, 1.5 tons of A4 paper, 3.46 tons of labels, 22.5 tons of paper ice boxes, 0.336 tons of plastic bags, 18.29 tons of cardboard boxes, and 9.4 tons of foam boxes.

TALENT DEVELOPMENT

ECOLOGICAL CO-CONSTRUCTION



Resource use, energy consumption and investment in environmental protection facilities

Our company and its subsidiaries actively practice energy conservation and emission reduction by rationally utilizing water and electricity resources, reducing energy consumption to lower operational costs and protect the environment. During the reporting period, we continuously strengthened our investment in environmental protection, optimized production processes, and improved equipment efficiency, committing to environmental protection and energy saving. The environmental protection facilities established by the company are operating normally, ensuring that wastewater and exhaust gas treatment meet standards and that hazardous waste is disposed of in accordance with regulations.

The company's water supply primarily comes from municipal water services, mainly used for domestic water, air conditioning cooling water, and cleaning in research and development production. Biosino has established a corresponding water-saving system to ensure standardized water use in production and daily life, avoiding unnecessary waste of water resources.

• Water Resource Assessment and Monitoring: The company regularly assesses and monitors water resource usage to promptly identify

t	2024
neter	18566
h	1888464
1	460
1	3.92
1	4.89

- T

TALENT DEVELOPMENT

CORPORATE CULTURE AND THE CONCEPT OF EMPLOYING

From the beginning, Biosino has accumulated profound cultural heritage. It has built a career platform for employees through various institutional arrangements and organizational construction; And enter a cultural atmosphere at high speed through various exciting or warm activities.



Our Employees

Biosino has perfect system and standardized management, adheres to the principle of "respecting talents, trusting talents and understanding talents", creates a stage and opportunity for employees development, encourages employees to display their talents, makes the enterprise develop and grow by giving full play to employees talents, and reflects employees' own value through the development and growth of the enterprise.

Relevant employment systems include employee handbook, attendance and leave management system, salary management system of Biosino, performance appraisal management measures, probation management measures, employee transfer and promotion management measures, management measures for managers, welfare payment measures, harmony fund management measures, honor award regulations A series of regulations such as the regulations on the administration of labor insurance payment guarantee the rights and interests of employees, create fair and equal work opportunities for employees, provide rich welfare benefits, and provide protection for their career planning.

Biosino establishes and implements a sound salary incentive system, determines the post salary of personnel through different positions and ranks, establishes the salary system of R&D technicians, functional departments and sales personnel, establishes a reasonable rising channel, gives full play to the incentive role of salary. selects and reserves excellent talents according to the management personnel assessment methods and personnel promotion management methods, and establishes a talent reserve mechanism. Biosino abides by the provisions of the labor law, works within 8 hours a day, implements the two-day rest system, and provides annual leaves, marriage leaves, parental leaves and other legal holidays. The relevant subsidies include health care expenses, fever subsidies, professional title subsidies, age subsidies, cold storage subsidies, etc. The company provides employees with equal opportunities for recruitment and promotion. At the same time, it has a complete set of management systems and regulations, which are strictly implemented.

Business centers

Center	Biosino	Biosino Anhui	Biosino Jinyu	Biosino Suzhou	Biosino Technology Transfer
Executives	8	1	4	3	0
Marketing center	107	2	27	17	2
R&D center	34	0	26	18	0
Manufacturing center	62	0	50	38	1
Managementsupportcenterand0thers	48	17	9	24	1
Total	259	20	116	100	4

Education

Education Level	Biosino	Biosino Anhui	Biosino Jinyu	Biosino Suzhou	Biosino Technology Transfer
PhD	3	0	2	1	0
Master's	30	0	10	2	1
Bachelor's	117	4	32	23	3
Associate Degree and below	109	16	72	74	0
Total	259	20	116	100	4

Title

Professional Title	Biosino	Biosino Anhui	Biosino Jinyu	Biosino Suzhou	Biosino Technology Transfer
Senior	12	0	1	2	1
Intermediate	38	2	14	12	1
Junior	44	2	3	56	2
None	165	16	98	30	0
Total	259	20	116	100	4

Age

Age Group	Biosino	Biosino Anhui	Biosino Jinyu	Biosino Suzhou	Biosino Technology Transfer
20-30 years old	44	11	19	23	1
31-40 years old	111	5	28	68	2
41-50 years old	80	4	49	8	0
51-60 years old	24	0	20	1	1
Total	259	20	116	100	4

Gender					
Gender	Biosino	Biosino Anhui	Biosino Jinyu	Biosino Suzhou	Biosino Technology Transfer
Male	149	7	45	59	1
Female	110	13	71	41	3
Total	259	20	116	100	4

Disclosure of Employee Onboarding and Turnover Rates

The company provides equal opportunities for onboarding and promotion for each employee, and has a well-enforced management system and regulations in place. Last year, Biosino adjusted its organizational structure, strengthened performance evaluations and personnel management, and reinforced an internal merit-based system. This system, through evaluations, eliminated the last unfit personnel element, optimized the personnel structure, and improved staff efficiency, leading to some departures. Additionally, there were employees who left for personal reasons, including not adapting to new positions after job changes, relocating to places far from the company, and seeking other personal development opportunities.

Employment Type Employee Turnover Rate and Entry Rate by Gender 1.2 -0.25 1 -0.2 0.15 0.6 01 0.05 0.2 Onboarding Rate Turnovor Pate Male Female





ECOLOGICAL

23 Development and Training

Biosino has seven training types: senior management training, middle-level management training, marketing training, professional technical training, professional skill training, general training for all staff and new employee training, including company level, department level and team level. Conduct in-depth training demand analysis for various types of training, enhance the pertinence of training contents, strengthen the tracking assessment and evaluation of trainees, apply what they have learned, develop in an every expect, and improve the comprehensive quality and ability of employees through various trainings.

The company offers seven types of training: senior management training, middle management training, marketing training, professional technical training, professional skill training, general training for all employees, and new employee training. Training is conducted at three levels: company, department, and team. An in-depth training needs analysis is conducted for various types of training to enhance the relevance of the training content, strengthen the follow-up assessment and evaluation of the trainees, apply what is learned, develop comprehensively, and improve the overall quality and capability of the employees through various training programs.

In 2024, the company's quality management system, safety production system, and other training management systems operated well. There were 40 sessions on the dissemination of laws and regulations related to the production and operation of medical devices, 30 sessions of new employee training, 32 sessions of medical device operation system and production management system training, 1 session of ESG training, and more than 20 training sessions on fire protection, occupational health, work safety, biosafety, work safety management, intellectual property rights, and corporate law, etc.

Business Training



Sales Manager Training



System Training

Fire Protection Training



Employee Training Coverage: 100%

2024 Training Overview

Training Situation by Gender

Training Situation by Job Level

- T

Gender	Total Trainees	Percentage	Total Training Hours	Job Level	Total Trainees	Percentage	Total Training Hours
Male	1259	46.41%	764	Manager	405	14.93%	408
Female	1454	53.59%	990	Staf	2308	85.07%	1346
Total	2713	100%	1754	Total	2713	100%	1754

Average Training Hours Per Employee

Gender	Average Hours per Person	Job Level	Average Hours per Person
Male	2.1	Manager	4.1
Female	3.4	Staff	2.4

The company strictly implements and enforces the provisions of laws and regulations such as the "Labor Law of the People's Republic of China," eliminating the employment of child labor and forced labor. Through regular employee training and a robust internal reporting mechanism, we ensure the complete eradication of employing child labor and forced labor in our business operations. In the recruitment process, we adhere to China's employment laws and regulations, uphold the principles of fairness and equality, and provide equal employment opportunities to all candidates. For behaviors that violate our policies, we will take the necessary disciplinary actions. During the reporting period, there were no incidents of forced labor or employment of child labor.

Assessment and incentive

Biosino has formed a performance appraisal system based on KPI and balanced scorecard. Based on the post responsibilities of senior managers, set assessment indicators according to the Company's strategic objectives and budget decomposition at the beginning of each year, sign performance assessment letters and conduct performance assessment level by level. By the end of the year, their salaries had not been approved according to their performance indicators, and the performance evaluation standards and assessment procedures of senior managers had been effectively implemented. And make corresponding amendments and improvements according to the implementation.

At the same time, Biosino has established a targeted and operational evaluation and incentive mechanism at all levels, so as to further improve the corporate governance structure and all staff incentive mechanism, fully mobilize the enthusiasm of management and key employees, effectively combine the interests of shareholders, the company and the personal interests of operators, and make all shareholders pay attention to the long-term development of the company.

Biosino has established an internal control system, and the effectiveness and rationality of the system are supervised and evaluated through internal audit. The effective internal control system ensures the effective implementation of applicable laws and internal systems, effectively reduces the risk of corruption and violation, and improves the operation ability of the company.

Biosino has issued additional domestic shares to key employees, further strengthened the incentive mechanism for senior managers and key personnel, and promoted the long-term and stable development of the company.

OCCUPATIONAL HEALTH AND SAFETY

The company places a high emphasis on the occupational health of its employees, aiming to prevent occupational health. In accordance with regulatory requirements, the company organizes occupational health examinations for relevant personnel and has established a dedicated Occupational Health Committee and working group. Occupational health and safety education and publicity columns have been set up to disseminate regulations and system requirements, enhancing the protection of employee occupational health. Labor protection supplies are provided and regularly replaced to ensure their effectiveness and safety. In terms of occupational health management, the company has achieved annual detection of occupational hazard factors and a triennial evaluation; employees in positions involving occupational health surveillance record is established for each employee involved in occupational hazards; pre-employment, post-employment, and regular on-the-job occupational health examinations are conducted to track employees' health status, and employees found to have occupational contraindications through medical examinations are reassigned to prevent the occurrence of occupational diseases. Since initiating its work on achieving standards in production safety in 2014, the company has established a leadership group for production safety, an occupational health leadership group, a biosafety committee, and a leadership team. It was awarded the "National Second-Level Standard Enterprise for Safety Production" in 2014, and achieved the "Third-Level Standard Enterprise for Safety Production" and the "Beijing Municipal Occupational Health Infrastructure Standard Unit" in 2021. The company supervises and manages all aspects of work related to safety production, biosafety, and occupational health in accordance with regulatory requirements in both production and business operations.

To establish biosafety protection procedures and strengthen the biosafety management of laboratories and production workshops to protect the health of laboratory and production workshop workers and ensure the surrounding environment is not contaminated by pathogenic microorgan-isms, Biosino has established "Biosafety Protection Procedures," including biosafety protection procedures for laboratories and production workshops and emergency response measures. In addition, Biosino has established related documents such as "Waste Management Procedures," "Personnel Entry and Exit Management Procedures for Production Areas," "Site Clearance Management Procedures," and "Cleaning Procedures for Containers and Equipment." During the reporting period, the group implemented a safety production responsibility system at all levels, taking the construction and implementation of the safety management system in the company and its subsidiaries seriously. Through comprehensive compliance risk assessments, team formation and professional capacity building and enhancement, facility upgrades and renovations, periodic independent inspections and audits, hazard reporting and rectification, and technical support and response for improvement projects, the management and improvement. The group has organized and implemented centralized professional training and other related safety management and improvement activities, significantly reducing the safety risks in its operations, standardizing employee operation management, and deeply embedding safety concepts and culture. In terms of resource conservation and environmentally friendly construction, the group focuses on the application and promotion of energy-saving technologies and energy contract management projects, achieving good economic and environmental benefits.

- Safety education and training coverage rate: 100%
- Safety risk prevention training coverage rate: 100%
 Occupational injury insurance coverage rate for
- employees: 100%
- Employee health examination coverage rate: 100%



The organization has implemented occupational health examinations, occupational health training, and occupational health declarations among other occupational health management tasks, ensuring the smooth progress of occupational health management work. In 2024, the monitoring of occupational health factors in the environment was completed, in compliance with industry regulations.



ECOLOGICAL CO-CONSTRUCTION

Strategic Cooperation



(1) On February 28th, 2024, Mr. Chen Peng, the President of Biosino, Mr. Yao Chunfeng, the Marketing Director and General Manager of Zhongke Jinchen, and Professor Nie Jinfu, the Chief Scientist of Zhongke Jinchen and Biosino Precision Medicine Laboratory under Biosino, were invited to visit and inspect the Hong Kong Innovation Institute of the Chinese Academy of Sciences. They aimed to contribute to the mutual promotion of industries and science

(2) On October 18, 2024, Biosino's affiliated company, Zhongke Beisheng (Beijing) Holding Co., Ltd., and Beijing Zhongke Guoxing Innovation Service Co., Ltd., affiliated with Country Garden Services, signed a nationwide strategic cooperation agreement in Beijing. The collaboration focuses on innovatively advancing smart logistics services for medical institutions and community health and wellness services.



EMPOWERING TEAMS AND INDUSTRY GROWTH

On June 3rd, the "Experts Entering Enterprises" series of activities organized by the Science and Technology Association of Changping District was successfully held at our company. This event invited renowned experts in the field of intellectual property rights to provide a splendid intellectual property rights training session for our employees, enhancing their awareness and protection consciousness regarding intellectual property rights. The experts delivered a lecture in an easy-to-understand manner, covering topics such as patents, basic rights concepts, relevant intellectual property regulations, as well as issues related to cooperation or commissioned research and development, and patent transfer. This enabled our employees to gain a more comprehensive and in-depth understanding of intellectual property rights. Additionally, the experts analyzed the significant role of intellectual property rights in the development of enterprises based on real cases. Through these cases, our employees learned how intellectual property rights drive technological innovation in enterprises, protect the legitimate rights and interests of enterprises, and play an important role in market competition.



Development Trends".

SUPPLY CHAIN ESG MANAGEMENT

To ensure suppliers meet the company's requirements and expectations, and to manage suppliers efficiently, the company has established a comprehensive supplier management system. The company conducts supplier management activities in accordance with the "Supplier Evaluation and Control Procedure" and the "Purchasing Control Procedure."

The "Supplier Evaluation and Control Procedure" enables the effective selection, evaluation, and control of suppliers to ensure that the products and services they provide meet the company's requirements for production, research and development, testing, and services. The supplier evaluation team, consisting of heads from the company's quality management department, finance department, reagent factory, purchasing department, R&D department, and quality control department, is responsible for assessing suppliers' quality systems and determining qualified suppliers.

On October 12, 2024, at the Continuing Education Learning Class on New Advances in Flow Cytometry and Cellular Immunology held by Biosino Hefei, the employees of Biosino Hefei listened to the report titled "Verification of Domestic Flow Cytometry Performance and Its

The company conducts a comprehensive assessment of suppliers' "quality systems" covering aspects such as factory premises, personnel and training, material management, equipment, documentation, production technical management, quality management, subcontracting or subcontracted testing products, delivery, contract signing, and after-sales service. At the same time, based on the "Regulations on the Supervision and Management of Medical Device Production," "Good Manufacturing Practice for Medical Devices," "Guidelines for Medical Device Manufacturer Supplier Audits," and other applicable laws, regulations, and industry standards, the company sets requirements for suppliers to ensure the quality of supplied products.

For Class A material suppliers, who contribute to the main or critical parts of the company's final product, approval is given only when they meet requirements in qualifications, quality management system, personnel qualifications, and sample evaluations. Additionally, the purchasing department re-evaluates the qualifications of qualified material suppliers every six months, internally scoring suppliers on supply quality, delivery time, usage, after-sales service, etc., and eliminating suppliers that do not meet standards.

- A-type materials: Main or critical components of the final product that significantly affect the quality or safety performance of the product, mostly including enzymes and antiserums, and materials for internal packaging that come into direct contact with reagents.
- B-type materials: Materials that constitute non-critical parts of the final product, generally not affecting the final product's quality, or if they do have a slight impact, corrective measures can be taken. These are all materials other than A-type materials.
- C-type materials: External packaging materials (labels, packaging boxes, shipping cartons, etc.).

Supply Chain Risk Management

In the realm of supply chain risk identification and management, Biosino North Control has implemented the following measures:

- Risk Identification: The company regularly assesses supply chain risks, including but not limited to financial stability of suppliers, geopolitical risks, natural disasters, market fluctuations, and supply chain disruptions. Potential supply chain risks are identified through data analysis and market research.
- Risk Assessment: Identified risks undergo quantitative and qualitative analysis to evaluate their potential impact on the company's supply chain. Risks are categorized and prioritized based on their severity and probability of occurrence.
- Risk Control: For high-risk suppliers, the company intensifies monitoring and management, taking preventive measures such as increasing inventory, finding alternative suppliers, and signing long-term contracts. Agreements are signed with suppliers to ensure that they bear the risk liability before our company's acceptance inspection is passed; after passing, the demand side bears the liability, except in cases where the quantity or quality of the internal packaging provided by the supplier does not meet requirements, in which the supplier still bears the risk liability.
- Risk Monitoring: A risk monitoring mechanism is established to regularly track changes in supply chain risks and adjust risk management measures timely. Supplier performance and risk indicators are monitored through data collection and analysis.
- Emergency Plan: An emergency plan for the supply chain is developed to respond to sudden events and crises, ensuring rapid activation of alternative suppliers in the event of supply chain disruptions or other emergencies, minimizing impact on production and operations.
- Continuous Improvement: The supply chain risk management process is continuously optimized through ongoing improvement efforts. Suppliers are encouraged to participate in risk management activities, establishing long-term partnerships to jointly reduce supply chain risks.

Biosino North Control is committed to building a more stable and reliable supply chain system to address various potential risks, ensuring the company's continued development and competitive advantage.

Supplier ESG Training

On the morning of January 18, 2024, Biosino North Control invited ESG experts to conduct ESG training for the company's supplier representatives and leaders, Biosino North Control executives, and department heads, chaired by Mr. Wu Lebin, the chairman of Biosino North Control. Mr. Wu started with real data on environmental governance, discussing the significant impact of carbon assessments on the ecological chain and environment, and highlighted the importance of implementing carbon assessments throughout the entire process of product development, production, transportation, and sales, including the supply chain. Mr. Wu hopes that everyone will incorporate low-carbon and green concepts into their actions and proposed that the company's green development should "start with me, start with the supply chain, and start now."



During the reporting period, the company actively promoted the strategy of substituting domestic materials for imported ones to reduce dependence on external resources and enhance the stability and sustainability of the supply chain. Through strengthening cooperation with domestic suppliers and optimizing procurement processes, the company has not only successfully reduced costs but also improved the quality and supply efficiency of raw materials. Additionally, domestic substitution helps shorten the supply chain, reduce carbon emissions in logistics, and aligns with our commitment to environmental protection and sustainable development. Key raw materials such as CHE and ADA have been substituted with domestically developed alternatives, and some suppliers from the United States, Japan, and other countries have been replaced with domestic ones, further enhancing the domestic level and competitiveness of our products. We believe that through continuous effort and innovation, we can provide our customers with higher quality, more environmentally friendly products, while positively contributing to national industrial upgrading and green development goals.

Domestic supplier proportion: 86%







GOVERNANCE PRODUCT RESEARCHAND DEVELOPMENT AND GREEN AND LOW-CARBON INNOVATION DEVELOPMENT TALENT DEVELOPMENT

PARTICIPATE IN THE FORMULATION OF INDUSTRY STANDARDS AND GROUPS STANDARDS

For enterprises, participating in the development of national, industry, and group standards holds significant importance. It not only allows them to adjust product quality proactively, seizing market opportunities early on, but also enhances the company's reputation within the industry and market, thereby building the corporate brand. Furthermore, it can guide the development direction of the industry, and even lead to a repositioning of the industry, increasing market recognition of the company's products. This, in turn, can expand market share and enhance competitiveness. Currently, Biosino North Control has drafted and published a total of 24 national, industry, and group standards.

Industry standards and group standards

No.	Standard Name	Standard Number	Implementation Date
1	a-Amylase Assay kit (continuous Monitoring Method)	YY/T 1194-2011	2013/6/1
2	Reference Measurement procedure for Total serum protein	YY/T 1195-2011	2013/6/1
3	Purified Water for in vitro Diagnostic Reagents	YY/T 1244-2014	2015/7/1
4	Lactate Dehydrogenase Assay kit	YY/T 1241-2014	2015/7/1
5	a-Hydroxybutyrate Dehydrogenase Assay kit	YY/T 1242-2014	2015/7/1
6	Creatine kinaseAssay kit	YY/T 1243-2014	2015/7/1
7	CystatincAssay kit	YY/T 1230-2014	2015/7/1
8	Alkaline phosphatase Assay kit (Npp substrate-AMp Bufer Method)	YY/T 1234-2014	2015/7/1
9	Total protein Assay kit	YY/T 1444-2016	2017/1/1
10	Lipoprotein (a) Test kit	YY/T 1448-2016	2017/1/1
11	Carbon Dioxide Assay kit	YY/T 1523-2017	2018/4/1
12	C-Reactive protein Assay kit	YY/T 1513-2017	2018/4/1
13	Creatine kinase-MB Isoenzyme Assay kit	YY/T 1580—2018	2019/3/1
14	Heart-Type Fatty Acid-Binding protein Assay kit (Immunoturbidimetry)	YY/T 1590—2018	2019/3/1
15	Glycated Hemoglobin Assay kit (Latex Immunoturbidimetry)	YY/T 1605—2018	2019/3/1
16	Allergen-specific 1gE Antibody Test kit	YY/T 1581—2018	2019/3/1
17	Uncertainty Evaluation of calibration Material for ln vitro Diagnostic Reagents	YY/T 1709—2020	2021/12/1
18	Performance Evaluation Methods for ln vitro Diagnostic Testing systems part 1: precision	YY/T 1789.1-2021	2023/3/1
19	Deafness Gene Mutation Test kit	YY/T 1800-2021	2023/3/1
20	Serum Amyloid A Assay kit	YY/T 1880-2022	2023/10/1
21	Triglyceride Assay kit (Enzymatic) Revision	YY/T 1199—2023	2023/7/15
22	Requirements for Quantitative Measurement of Biogenic samples in ln vitro Diagnostic MedicalDevicesandsupportingDocumentcontentforcertifiedReference Materials	GB/T 19703-2020	2021/12/1
23	Guide for the Application of value Assignment to ln vitro Diagnostic calibration	T/ZMDs 40001-2021	2021/8/25
24	Materials Glucose Assay Kit (Enzymatic Method)	YY/T 1200-2024	2024/2/7

EXHIBITION APPEARANCES

innovative technologies. In 2024, Biosino participated in a total of 7 major domestic and international exhibitions. (1) From February 5th to 8th, Biosino made an appearance at the Arab International Medical Laboratory Instruments and Equipment Exhibition, presenting new products and new technologies; (2) From March 16th to 18th, it brought along the 3-color 15-spectrum flow cytometer BioCyte and other star products to participate in CACLP (Chongqing), and launched the "Jin Gang 9000 Series" intelligent pipeline during the exhibition; (3) From August 15th to 17th, it made an appearance at the 13th OCLM (Eastern Laboratory Medicine Academic Conference) in Shanghai, and the AutoProSample A960 & BioCyte fully automatic flow cytometer workstations made their debut for the first time:

(4) From August 22nd to 24th, the AutoProSample A960 & BioCyte fully automatic flow cytometer workstations were officially launched at NCLM (Hangzhou), ushering in a new era of flow cytometry automation; (5) From August 30th to September 1st, it participated in the China Heart Conference (CHC) in Beijing with the bedside cardiac biomarker detection instrument PATHFAST;

(6) From October 11th to 13th, it participated in the 18th Beijing Medical Association Laboratory Medicine Academic Conference and exhibited the AutoProSample A960 & BioCyte fully automatic flow cytometer workstations and PATHFAST; (7) From November 11th to 14th, it participated in the 2024 Düsseldorf International Medical and Medical Device Expo in Germany, presenting the 3-color 15-spectrum flow cytometer BioCyte.



- Biosino actively participates in important domestic and international exhibitions to showcase its newly launched products and

GOVERNANCE PRODUCT RESEARCHAND DEVELOPMENT AND GREEN AND LOW-CARBON INNOVATION DEVELOPMENT TALENT DEVELOPMENT

COMMUNITY INVOLVEMENT

To implement the "Spring Returns to Changping, Beautiful Homeland" themed environmental improvement campaign initiated by Changping District, the company has organized its employees to participate in related activities within the surrounding communities.



Since its establishment in 2005, Biosino North Control has created the Corporate Harmony Development Fund, primarily aimed at providing congratulations gifts for the marriage of employees, their children's high school entrance exams, offering financial support for the illness of employees and their immediate family members, and disbursing honor bonuses to retired employees, with a cumulative disbursement of over 1 million yuan. During the reporting period, the expenditure of the Harmony Development Fund included condolence payments for the death of immediate family members of employees and support funds for children's education, totaling 10,000 yuan.

APPENDIX I: INDEX TABLE OF HKEX ESG REPORTING GUIDE

Subject Areas' Aspects	' General Disclosures and KPIs chapt	er and page
A. Environment		
Aspect A1	Emissions	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air emissions, discharges into water and land, and generation of hazardous and non-hazardous waste. Note: Air emissions include NOx, SOx, and other pollutants regulated under national laws and regulations. Hazardous wastes are those defined by national regulations.	P24-25 P29-30
KPI A1.1	The types of emissions and respective emissions data.	P26-28 P30
KPI A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	P30
KPI A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	n P30
KPI A1.5	Description of emission target(s) set and steps taken to achieve them.	P24-29
KPI A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	P24/P29
Aspect A2	Use of Resources	
General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials. Note: Resources may be used in production, in storage, transportation, in buildings, electronic equipment, etc.	P30
KPI A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	P30
KPI A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	P30
KPI A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	P24/P28-29
KPI A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	P24/P30
KPI A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	P30
Aspect A3	The Environment and Natural Resources	
General Disclosure	Policies on minimising the issuer's significant impacts on the environment and natural resources.	P24
KPI A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	P24-25/P29-30
Aspect A4	Climate Change	
General Disclosure	Policies on identification and mitigation of significant climate-related issues which have impacted, and tho which may impact, the issuer.	se P25
KPI A4.1	Description of the significant climate-related issues which have impacted, and those which may impact, the issuer, and the actions taken to manage them.	P24-29





APPENDIX I: INDEX TABLE OF HKEX ESG REPORTING GUIDE

Babycet meas mspects	' General Disclosures and KPIs chapter	and page
B. Social		
Aspect B1	Employment	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	P31-32
KPI B1.1	Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.	P32-33
KPI B1.2	Employee turnover rate by gender, age group and geographical region.	P33
Aspect B2	Health and Safety	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	Р36
KPI B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	P36
KPI B2.2	Lost days due to work injury.	P36
KPI B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	P36
Aspect B3	Development and Training	
General Disclosure		
	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities. Note: Training refers to vocational training. It may include internal and external courses paid by the employer.	P34-35
KPI B3.1	training activities. Note: Training refers to vocational training. It may include internal and external courses	P34-35 P35
	training activities. Note: Training refers to vocational training. It may include internal and external courses paid by the employer. The percentage of employees trained by gender and employee category (e.g. senior management, middle	
КРІ ВЗ.1	training activities. Note: Training refers to vocational training. It may include internal and external courses paid by the employer. The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	P35
КРІ ВЗ.1 КРІ ВЗ.2	 training activities. Note: Training refers to vocational training. It may include internal and external courses paid by the employer. The percentage of employees trained by gender and employee category (e.g. senior management, middle management). The average training hours completed per employee by gender and employee category. 	P35
КРІ ВЗ.1 КРІ ВЗ.2 Aspect B4	 training activities. Note: Training refers to vocational training. It may include internal and external courses paid by the employer. The percentage of employees trained by gender and employee category (e.g. senior management, middle management). The average training hours completed per employee by gender and employee category. Labour Standards Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a 	P35
KPI B3.1 KPI B3.2 Aspect B4 General Disclosure	 training activities. Note: Training refers to vocational training. It may include internal and external courses paid by the employer. The percentage of employees trained by gender and employee category (e.g. senior management, middle management). The average training hours completed per employee by gender and employee category. Labour Standards Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour. 	P35 P35 P35
KPI B3.1 KPI B3.2 Aspect B4 General Disclosure KPI B4.1	 training activities. Note: Training refers to vocational training. It may include internal and external courses paid by the employer. The percentage of employees trained by gender and employee category (e.g. senior management, middle management). The average training hours completed per employee by gender and employee category. Labour Standards Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour. Description of measures to review employment practices to avoid child and forced labour. 	P35 P35 P35 P35 P32/P35
KPI B3.1 KPI B3.2 Aspect B4 General Disclosure KPI B4.1 KPI B4.2	 training activities. Note: Training refers to vocational training. It may include internal and external courses paid by the employer. The percentage of employees trained by gender and employee category (e.g. senior management, middle management). The average training hours completed per employee by gender and employee category. Labour Standards Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour. Description of measures to review employment practices to avoid child and forced labour. 	P35 P35 P35 P35 P32/P35

APPENDIX I: INDEX TABLE OF HKEX ESG REPORTING GUIDE

Aspect B5	Supply Chain Management	
KPI B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	P39
KPI B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	P39
KPI B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	P38-40
Aspect B6	Product Responsibility	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	P16-17
KPI B6.1	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	P20
KPI B6.2	Number of products and service related complaints received and how they are dealt with.	P23
KPI B6.3	Description of practices relating to observing and protecting intellectual property rights.	P18-19
KPI B6.4	Description of quality assurance process and recall procedures.	P20-21/P23
KPI B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	P20
Aspect B7	Anti-corruption	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	P11
KPI B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	P11
KPI B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	P11
KPI B7.3	Description of anti-corruption training provided to directors and staff.	P11
Aspect B8	Community Investment	
General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	P43
KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	P38/P43
KPI B8.2	Resources contributed (e.g. money or time) to the focus area.	P43

READER FEEDBACK

Dear Reader,

Thank you for reading this report. This is the forth time we have independently published an ESG report. We sincerely hope that you can evaluate this report and provide us with your valuable feedback to help us continuously improve.

Feedback survey:

Did you find the information you needed in this report?

What additional information do you think should be included in this report?

Do you have any other suggestions for this report?

Contact person: Xiaoming Ma

Address: No. 27, chaoqian Road, changping District, Beijing

Email: mxm@zhongsheng.com.cn



